Automated Multiplex Immunofluorescence
Cancer research continues to push the boundaries with new advancements in tissue analysis and biomarker detection. Now, more than ever, there is significant emphasis on understanding the underlying interaction between the immune system and the tumor microenvironment. Multiplexing immunofluorescence (mIF) has greatly increased our understanding of solid tumor biology and immunology, including tumor-infiltrating lymphocytes and cancer-induced architectural alterations, and aided in novel immunology discoveries. In this webinar, we will discuss how Akoya Biosciences Phenoptics assays support quantitative mIF to overcome the limitations imposed by conventional IHC methodologies. We will also discuss how our Opal assay kits and reagents can be integrated with the Leica BOND RX to automate your staining workflow to support consistent results for high-throughput studies.
- Understand the limitations of conventional IHC, and the benefits of transitioning to multiplex immunofluorescence
- Learn how to design, optimize and analyze your multiplex assay panel
- Understand how the BOND RX enables innovations like the Opal assay
For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted. Leica Biosystems and the editors hereby disclaim any liability arising directly or indirectly from the use of the content, including from any drugs, devices, techniques or procedures described in the content.
Copyright © 2020 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.